Objectives: The aim of this study was to identify factors that affect the clinical course, outcome, and duration of hospital stay in patients with a brain abscess. Methods: Eighty-four inpatients with a confirmed brain abscess were the subjects of this retrospective study. The impact of several factors on the length of hospital stay was evaluated and multiple linear regression analysis was used. Results: Several factors affecting the length of hospitalization were identified. These were older age and larger abscess diameter. Conclusions: Proper handling of preexisting infections and early consideration of CNS infection, especially in high-risk groups, may reduce the incidence of brain abscess and improve its prognosis. The factors affecting the length of hospitalization shown in this study should be considered upon admission to reduce patients’ unfavorable outcomes.

Objectives: This study aimed to examine the incidence of symptoms that indicate neurological or pulmonary complications after recovery from mild to moderate COVID-19.Methods: The study included 138 adult outpatients who underwent testing that included chest X-ray (CXR), complete blood count (CBC), C-reactive protein (CRP), interleukin 6 (IL-6), and D-dimer assessments during the acute phase of the illness. In addition, 30 days after being classified as convalescent, serological tests for IgM and IgG antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) were performed, and the patients were asked to complete a survey assessing their overall wellbeing.Results: The most common sequelae included decreased physical efficiency (35%), weakness (24%), difficulty concentrating (16%), and memory problems (15%), which were correlated with abnormal chest X-ray findings. Seroconversion to anti-SARS-CoV-2 IgG was detected in 49 (87.5%) out of 56 patients tested and was more common among those with a more severe course of the infection.Conclusion: Individuals with mild to moderate COVID-19 are likely to experience persistent neurocognitive symptoms. Patients with initial abnormal chest X-ray findings and elevated inflammatory parameters are more likely to seroconvert to anti-SARS-CoV-2.

Background/Objectives: Secondary bacterial infections in subjects hospitalized with COVID-19 are associated with longer hospital stays and an increased risk of death. Thus, identifying the risk factors associated with bacterial complications in patients with SARS-CoV-2 infection is clinically important. Methods: We analysed the collected records of all adult patients diagnosed with an acute COVID-19 infection who were admitted to the Hospital for Infectious Diseases in Warsaw, Poland, between March 2020 and November 2021. Logistic regression models were used to identify factors associated with bacterial infections complicating the SARS-CoV-2 course. Results: The records of 1963 patients were analysed; 1128 (57.4%) of the patients were male, the median age of the cohort was 63 years (IQR: 50–74 years), and 202 patients (10%) died. A bacterial infection complicating the course of COVID-19 was diagnosed in 351 (18%) patients. In a multivariate logistic regression model the only factors identified as independently associated with an increased odds of bacterial infection were age (OR per decade: 1.21, p = 0.016), length of hospitalization (OR per day: 1.12, p < 0.001), and D-dimer concentration (OR per 500 units: 1.01, p = 0.048). Conclusions: Shortening the length of hospitalization of patients with COVID-19 can reduce the risk of bacterial infection complications, especially in elderly individuals. Coagulation system activation in COVID-19 patients increases the risk of a bacterial infection.

Background and Clinical significance: This case describes a patient with a complex medical history who develops an active Mycobacterium tuberculosis (MTB) infection. The complex multidrug regimen has led to significant drug–drug interactions (DDIs) and adverse effects. This case highlights an urgent need for standardized guidelines on dose adjustment and therapeutic monitoring for opioid substitution therapy (OST) and antiretroviral therapy (ART) during MTB treatment to prevent adverse health outcomes and ensure clinical success. Case Presentation: A 43-year-old man with medical history including human immunodeficiency virus (HIV), chronic hepatitis C virus (HCV), psychotic disorder, and opioid dependence maintained on buprenorphine (24 mg/day) presented with acute psychosis and respiratory symptoms. During hospitalization, he was diagnosed with MTB infection and was started on an empirical rifampicin-based anti-MTB regimen. His clinical course was complicated by reduced buprenorphine efficacy caused by rifampicin, which precipitated opioid withdrawal symptoms. Conclusions: The successful clinical stabilization with resolution of withdrawal syndrome, reduced agitation, and normalization of vital signs, including heart rate and blood pressure of this patient, was achieved through targeted management of pervasive DDIs. A strategic ART switch and careful buprenorphine dose titration during rifampicin therapy was the key factor. This case highlights that co-managing HIV, MTB, and opioid use disorder presents a significant challenge where unaddressed DDIs directly threaten treatment efficacy, a patient’s safety, and adherence, and may result in increased toxicity. The case underscores the critical need for proactive DDI assessment, interdisciplinary collaboration, and guideline development for medication optimization in people living with HIV receiving OST.